Preclinical Model Offers New Insights into Parkinson’s Disease Process
July 23, 2024
A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.
Prestigious MERIT Grant Funds Research on How the Immune System Can Banish HIV
July 17, 2024
Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to novel therapeutic strategies for thwarting or eliminating HIV. Dr. Brad Jones, associate professor of immunology in medicine in the Division of Infectious Diseases at Weill Cornell Medicine, was awarded a MERIT grant from the National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).
Machine Learning Helps Define New Subtypes of Parkinson’s Disease
July 16, 2024
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. In addition to having the potential to become an important diagnostic and prognostic tool, these subtypes are marked by distinct driver genes. If validated, these markers could also suggest ways the subtypes can be targeted with new and existing drugs.
The research was published on July 10 in npj Digital Medicine.
Scientists Identify Blood Vessel Repair Cells
July 3, 2024
Endothelial cells with a distinct gene-expression signature play a key role in the development and repair of blood vessels throughout life, according to a new study by Weill Cornell Medicine investigators.
Cornell Inventors Celebrated at Cross-Campus Event
July 1, 2024
At “Bearers of Innovation: A One Cornell Celebration,” the Center for Technology Licensing at Cornell University recognized researchers’ milestones in the intellectual property and commercialization process. In total, 105 Cornellians invented technologies that were licensed or optioned to industry partners during fiscal year 2023, and 54 lead inventors disclosed a technology for the first time during the same fiscal year.
New Predictors of Metastasis in Patients with Early-Stage Pancreatic Cancer
June 28, 2024
Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to an individual’s liver or elsewhere, such as the lung.
Entrepreneurship Fuels Scientific Advancement for Early-Career Scientist
June 18, 2024
As an early-career academic scientist and budding entrepreneur, Dr. Cheuk Man Cherie Au has successfully obtained awards and grants for her groundbreaking research in drug development and the interest of potential investors. Dr. Au shared her innovation journey with Enterprise Innovation. Her passion, insights and experience navigating the realms of academia and entrepreneurship can serve as an inspiration to her peers and the wider Weill Cornell Medicine community.
2024 Business Plan Challenge Pitch Competition Supports Innovation for Health Care Challenges
June 18, 2024
“In this accelerator, we not only have our faculty explore their deep scientific questions but also help them expand their mindset to think of themselves as innovators and entrepreneurs,” said Loren Busby, director of BioVenture eLab, a part of Enterprise Innovation. She shared these remarks at the 2024 Business Plan Challenge pitch competition, which took place at Uris Auditorium on June 4.
Dr. Ashley Laughney Wins Pershing Square Sohn Prize for Young Investigators in Cancer Research
June 17, 2024
Dr. Ashley Laughney, an assistant professor of physiology and biophysics at Weill Cornell Medicine, has won a 2024 Pershing Square Sohn Prize for Young Investigators in Cancer Research.
Ultrasensitive Liquid Biopsy Tech Spots Cancer Earlier than Standard Methods
June 14, 2024
An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center (NYGC) and Memorial Sloan Kettering Cancer Center. The new technology has the potential to improve cancer care with the very early detection of recurrence and close monitoring of tumor response during therapy.